for transplanted livers
Proportions of populations living with harmful levels of liver fat
(Younossi et al, Hepatology 2016 )
Many donor livers are too unhealthy and so are discarded. A major reason for this is that many of these donor livers are just too fatty (a little like their owners). In fact, one in four of us live with harmful levels of liver fat. Ochre Bio develops genomic medicines to rejuvenate these donor livers before transplant, so that everyone who needs a new liver gets one.
The best part is that these therapies can be used to treat non-transplant patients too. Not only is liver fat a major reason for discarding donor livers, it’s now the main reason for patients needing a liver transplant. Fatty liver disease contributes to more deaths each year than all cancers combined.
We use genomics to find and shut down over-active genes driving disease and then go directly to testing our therapies in discarded donor livers that we keep alive outside of the body.
Our approach makes us better, cheaper, and faster than traditional drug discovery
High resolution cellular genomic technologies are at the core of what we do, which means we’re building the largest genetic atlas of the human liver and how it changes with fat build-up.
Our algorithms analyse over 250,000 data sets to help us not only find genes but the right combinations of genes for each patient.
We only work with humans, no animal testing here. We start by sequencing human livers, then test our therapies in human microlivers that we grow in the lab and in discarded human donor livers we keep alive outside of the body.
Jack is a biomedical engineer with background in bringing new health technologies to market. Jack helped get one of the first blockbuster gene therapies through FDA approval.
Quin is an MD and computational biologist. He founded his first liver drug company 15 years ago, co-steered Oxford's single-cell genomics consortium, and founded the Cellular and Systems Genomics department for a leading biopharma
Ochre Bio is within the heart of Oxford’s biotech innovation hub. Our scientific roots can be traced back to over 15 years leading liver genomics research and experience in bringing advanced therapies to market.
MR JACK O'MEARA
DR QUIN WILLS
Dawn is the Chief Scientific Officer and VP Medical Affairs for Novartis Canada
Peter is the co-founder and Chief Medical Officer, OrganOx. and Director of the Oxford Transplant Centre.
Leanne is the Professor of Metabolic Physiology at Oxford University, and co-Heads the Metabolic Research Group
Melissa is a thought leader in fatty liver disease, and previous Head of Liver Disease Development at Takeda
Alex is the Pfizer-Laubach Career Development Associate Professor, and member of the Broad Institute of MIT and Harvard
DR DAWN BELL
PROF PETER FRIEND
PROF LEANNE HODSON
DR MELISSA PALMER
PROF ALEX SHALEK